Blood-based monitoring identifies acquired & targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer July 16, 2019
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2+ breast cancer January 31, 2019 0